alendronate has been researched along with thiophenes in 47 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (2.13) | 18.2507 |
2000's | 10 (21.28) | 29.6817 |
2010's | 30 (63.83) | 24.3611 |
2020's | 6 (12.77) | 2.80 |
Authors | Studies |
---|---|
Hussar, DA | 1 |
Doggrell, SA | 1 |
Adami, S; Gatti, D; Viapiana, O | 1 |
Barton, IP; Boonen, S; Laan, RF; Watts, NB | 1 |
Barna, A; Bourgoin, M; Briot, K; Chapurlat, R; Christin-Maitre, S; Cortet, B; Costagliola, D; Diebolt, V; Dumarcet, N; Lacoin, F; Letombe, B; Nouyrigat, E; Oberlin, F; Orcel, P; Ravaud, P; Roux, C; Seret, P; Thomas, T; Veyries, ML; Vogel, JY; Yoldjian, I | 1 |
Briot, K; Roux, C; Thomas, T; Trémollières, F | 1 |
Díaz-Curiel, M; Moro Alvarez, MJ | 1 |
Rizzoli, R | 1 |
Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G | 1 |
Yee, J | 1 |
Foo, AC; Glendenning, P; Inderjeeth, CA; Lai, MM | 1 |
Breart, G; Cooper, C; Deltour, N; Meyer, O; Reginster, JY; Speirs, C | 1 |
Cai, DH; Chen, H; Deng, WM; He, L; Li, QN; Sun, P; Yang, L | 1 |
Delmas, P; Felsenberg, D; Frieling, I; Krieg, MA; Laroche, M; Rizzoli, R; Thomas, T | 1 |
Dorst, A; Farahmand, P; Ringe, JD | 1 |
Charle-Crespo, MÁ; Gomes-Carvalho, CS; Guerra-García, MM; Prejigueiro-Santás, A; Puga-Sarmiento, E; Rodríguez-Fernández, JB | 1 |
Eisman, JA; Jönsson, B; Kanis, JA; Papaioannou, A; Siris, ES; Ström, O; Tosteson, A | 1 |
Landfeldt, E; Lang, A; Robbins, S; Ström, O | 1 |
Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P | 1 |
Bock, O; Boutroy, S; Chapurlat, RD; Felsenberg, D; Frieling, I; Krieg, MA; Laib, A; Laroche, JM; Rizzoli, R; Thomas, T | 1 |
Gitlin, M; Jick, S; Li, L; Roddam, A; Shearer, A; Shepherd, S; Taylor, A | 1 |
Agholme, F; Aspenberg, P; Linderbäck, P; Närhi, T; Tengvall, P; Wermelin, K | 1 |
Cooper, C; Cortet, B; Diaz-Curiel, M; Kanis, JA; Lorenc, RS; Reginster, JY; Rizzoli, R | 1 |
Doschak, MR; Maksymowych, WP; Panahifar, A | 1 |
Jönsson, B; Kanis, JA; Ström, O | 1 |
Chen, B; Li, Y; Xie, D; Xu, H; Yang, X | 1 |
Huang, J; Kruse, M; Parthan, A; Taylor, D; Viswanathan, HN; Yurgin, N | 1 |
Chen, B; Li, Y; Xie, D; Yang, X | 1 |
Chapurlat, R; Chavassieux, P; Meunier, PJ; Pierre, M; Portero-Muzy, N; Roux, JP | 1 |
Capaldo, A; Di Somma, C; Gimigliano, F; Iolascon, G; Menditto, E; Orlando, V | 1 |
Hviid, A; Pasternak, B; Svanström, H | 1 |
Reid, IR | 1 |
Conti, V; Corbi, G; D'Argenio, V; Ferrara, N; Filippelli, A; Filippelli, W; Grimaldi, M; Maffulli, N; Russomanno, G; Simeon, V; Toro, G | 1 |
Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR | 1 |
Eiken, P; Vestergaard, P | 1 |
Bozzini, CE; Díaz, DH; Escudero, ND; Mandalunis, PM; Rodas, JA | 1 |
Huerta-Álvarez, C; Martín-Merino, E; Montero-Corominas, D; Prieto-Alhambra, D | 1 |
Ali, MS; Carbonell, C; Martinez-Laguna, D; Prieto-Alhambra, D; Reyes, C; Soria-Castro, A; Tebe, C | 1 |
Chan, CP; Chen, PL; Hsu, RW; Ju, YR; Lin, CY; Pan, WL; Pan, YC | 1 |
Álvarez-Gutierrez, A; Cooper, C; Delmestri, A; Hawley, S; Javaid, MK; Judge, A; Khalid, S; Llorente-Garcia, A; Martín-Merino, E; Petersen, I; Prieto-Alhambra, D; Van Staa, TP | 1 |
Chen, X; Geng, T; Guo, H; Jin, Q; Sun, S; Yu, H; Zhang, S; Zheng, M | 1 |
Fervers, F; Henrich, D; Kontradowitz, K; Leiblein, M; Marzi, I; Seebach, C | 1 |
Cherubini, K; de Figueiredo, MAZ; Koth, VS; Salum, FG | 1 |
Chen, R; He, H; Ma, C; Shi, C; Sun, B; Wu, H; Zhang, Y | 1 |
Ammann, P; Béhal, H; Boivin, G; Cortet, B; Falgayrac, G; Farlay, D; Gardegaront, M; Ponçon, C | 1 |
de Oliveira, GJPL; Gonçalves, FC; Marcantonio, RAC; Mascaro, BA; Scardueli, CR; Spolidorio, LC | 1 |
Abrahamsen, B; Arden, N; Calderon-Larranaga, S; Cooper, C; Hawley, S; Javaid, MK; Judge, A; Khalid, S; Prieto-Alhambra, D; Sami, A; Van Staa, TP | 1 |
10 review(s) available for alendronate and thiophenes
Article | Year |
---|---|
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Thiophenes | 2005 |
[Drug treatment of postmenopausal osteoporosis. What's New in 2006].
Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Body Mass Index; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Femoral Fractures; Follow-Up Studies; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Tablets; Teriparatide; Thiophenes; Time Factors | 2006 |
How long should patients take medications for postmenopausal osteoporosis?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Drug Monitoring; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Assessment; Teriparatide; Thiophenes; Time Factors; Treatment Outcome | 2007 |
Pharmacological treatment of osteoporosis for people over 70.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risedronic Acid; Thiophenes; Vitamin D | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D | 2007 |
Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Organometallic Compounds; Osteoporosis; Risedronic Acid; Teriparatide; Thiophenes | 2009 |
Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Thiophenes; Vitamin D | 2012 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Hydroxycholecalciferols; Ibandronic Acid; Imidazoles; Lumbar Vertebrae; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2015 |
Treatment of osteoporosis after alendronate or risedronate.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2016 |
Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Databases, Factual; Diabetes Mellitus; Diphosphonates; Humans; Myocardial Infarction; Osteoporosis; Primary Health Care; Renal Insufficiency, Chronic; Risk Assessment; Selective Estrogen Receptor Modulators; Thiophenes; United Kingdom | 2022 |
5 trial(s) available for alendronate and thiophenes
Article | Year |
---|---|
Recent important clinical trials of drugs in osteoporosis.
Topics: Aged; Alendronate; Animals; Calcitriol; Drug Therapy, Combination; Exercise Therapy; Female; Heart Transplantation; Humans; Meta-Analysis as Topic; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Risk Assessment; Thiophenes | 2004 |
Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femur Neck; Fractures, Bone; Hip Joint; Humans; Middle Aged; Organometallic Compounds; Osteogenesis; Osteoporosis, Postmenopausal; Spine; Thiophenes; Tibia; Tomography, X-Ray Computed | 2010 |
Efficacy of strontium ranelate on bone mineral density in men with osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Body Height; Bone Density; Bone Density Conservation Agents; Endpoint Determination; Fractures, Bone; Hip; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Prospective Studies; Spine; Thiophenes | 2010 |
Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Femur Neck; Finite Element Analysis; Humans; Lumbar Vertebrae; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Radius; Thiophenes; Tibia; Tomography, X-Ray Computed | 2012 |
Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate.
Topics: Administration, Oral; Alendronate; Biopsy; Bone and Bones; Female; Humans; Middle Aged; Osteoporosis; Thiophenes | 2014 |
32 other study(ies) available for alendronate and thiophenes
Article | Year |
---|---|
New therapeutic agents marketed in 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acarbose; Alendronate; Anti-Inflammatory Agents; Anti-Ulcer Agents; Carbonic Anhydrase Inhibitors; Drug Approval; Enzyme Inhibitors; Hypoglycemic Agents; Lansoprazole; Metformin; Omeprazole; Pregnadienes; Sulfonamides; Thiophenes; Trisaccharides; United States; United States Food and Drug Administration | 1996 |
Bone anabolic agents: the unanswered queries.
Topics: Alendronate; Anabolic Agents; Animals; Bone Resorption; Clinical Trials as Topic; Female; Humans; Male; Organometallic Compounds; Osteoporosis; Osteoporosis, Postmenopausal; Teriparatide; Thiophenes | 2004 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health | 2007 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Bone Density Conservation Agents; Calcium; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Kidney Failure, Chronic; Metoprolol; Nitroglycerin; Sulfonamides; Thiophenes | 2008 |
Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Epidemiologic Methods; Female; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Thiophenes; United Kingdom; Venous Thromboembolism | 2010 |
Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Glucocorticoids; Male; Methylprednisolone; Organometallic Compounds; Rats; Rats, Sprague-Dawley; Thiophenes | 2010 |
[Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Prescriptions; Etidronic Acid; Female; Hip Fractures; Humans; Incidence; Male; Middle Aged; Organometallic Compounds; Osteoporotic Fractures; Retrospective Studies; Risedronic Acid; Spain; Thiophenes | 2011 |
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Denosumab; Etidronic Acid; Female; Humans; Markov Chains; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Patient Compliance; Quality-Adjusted Life Years; RANK Ligand; Risedronic Acid; Thiophenes | 2011 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Male; Medication Adherence; Middle Aged; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Registries; Retrospective Studies; Risedronic Acid; Sweden; Thiophenes | 2011 |
Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
Topics: Administration, Oral; Aged; Alcoholism; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Case-Control Studies; Cohort Studies; Denmark; Diabetes Complications; Diphosphonates; Drug Therapy; Etidronic Acid; Female; Humans; Jaw Diseases; Male; Neoplasms; Organometallic Compounds; Osteitis; Osteomyelitis; Osteoporosis; Parathyroid Hormone; Periostitis; Radiotherapy; Raloxifene Hydrochloride; Risk Factors; Sjogren's Syndrome; Strontium; Thiophenes | 2012 |
Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Databases, Factual; Diphosphonates; Female; General Practice; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Patient Compliance; Postmenopause; Raloxifene Hydrochloride; Thiophenes; Time Factors; United Kingdom | 2012 |
Weak effect of strontium on early implant fixation in rat tibia.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Screws; Humans; Implants, Experimental; Male; Organometallic Compounds; Osteogenesis; Rats; Rats, Sprague-Dawley; Thiophenes; Tibia; X-Ray Microtomography | 2012 |
Potential mechanism of alendronate inhibition of osteophyte formation in the rat model of post-traumatic osteoarthritis: evaluation of elemental strontium as a molecular tracer of bone formation.
Topics: Alendronate; Animals; Arthritis, Experimental; Bone Density Conservation Agents; Drug Evaluation, Preclinical; Electron Probe Microanalysis; Female; Organometallic Compounds; Osteoarthritis; Osteogenesis; Osteophyte; Rats; Rats, Sprague-Dawley; Thiophenes; Tibial Meniscus Injuries; X-Ray Microtomography | 2012 |
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Drug Costs; Etidronic Acid; Female; Health Care Costs; Humans; Middle Aged; Models, Econometric; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; RANK Ligand; Risedronic Acid; Risk Assessment; Thiophenes; United Kingdom | 2013 |
Zoledronic acid enhances bone-implant osseointegration more than alendronate and strontium ranelate in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Evaluation, Preclinical; Female; Femur; Humans; Imidazoles; Materials Testing; Orthopedic Fixation Devices; Osseointegration; Osteoporosis, Postmenopausal; Ovariectomy; Prostheses and Implants; Rats; Stress, Mechanical; Thiophenes; Tibia; Titanium; Zoledronic Acid | 2013 |
Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Etidronic Acid; Female; Health Care Costs; Humans; Insurance, Health, Reimbursement; Markov Chains; Osteoporosis, Postmenopausal; Risedronic Acid; Sweden; Thiophenes; United States | 2013 |
Comparable effects of alendronate and strontium ranelate on femur in ovariectomized rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Drug Evaluation, Preclinical; Female; Femur; Ovariectomy; Rats; Rats, Sprague-Dawley; Thiophenes | 2013 |
Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Etidronic Acid; Female; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Thiophenes | 2013 |
Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Risedronic Acid; Thiophenes | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
A polymorphism at the translation start site of the vitamin D receptor gene is associated with the response to anti-osteoporotic therapy in postmenopausal women from southern Italy.
Topics: Alendronate; Bone Density Conservation Agents; Case-Control Studies; Female; Humans; Italy; Middle Aged; Osteoporosis; Polymorphism, Single Nucleotide; Postmenopause; Receptors, Calcitriol; Thiophenes; Treatment Outcome | 2015 |
Sequential administration of alendronate and strontium ranelate: histomorphometry and bone biomechanics in ovariectomized animals.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density Conservation Agents; Female; Ovariectomy; Rats; Rats, Wistar; Thiophenes | 2016 |
Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Primary Health Care; Risk Factors; Spain; Teriparatide; Thiophenes; Withholding Treatment | 2017 |
One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Databases, Factual; Denosumab; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Sensitivity and Specificity; Social Class; Spain; Teriparatide; Thiophenes | 2017 |
Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Thiophenes | 2017 |
Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Humans; Male; Middle Aged; Primary Health Care; Risk Assessment; Spain; Teriparatide; Thiophenes; United Kingdom; Venous Thromboembolism | 2018 |
Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice.
Topics: Aged; Alendronate; Animals; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Female; Humans; Mice; Osteocalcin; Osteoclasts; Osteogenesis; Osteolysis; Osteoporosis; Osteoprotegerin; Prosthesis Failure; Thiophenes | 2018 |
Do antiosteoporotic drugs improve bone regeneration in vivo?
Topics: Absorptiometry, Photon; Alendronate; Alkaline Phosphatase; Animals; Biomechanical Phenomena; Blotting, Western; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Regeneration; Bony Callus; Calcium-Regulating Hormones and Agents; Collagen Type I; Female; Femur; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Macrophage Colony-Stimulating Factor; Osteocalcin; Osteogenesis; Osteogenesis, Distraction; Parathyroid Hormone; Raloxifene Hydrochloride; RANK Ligand; Rats; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Thiophenes; Tomography, X-Ray Computed | 2020 |
Morphological and immunohistochemical features of tooth extraction sites in rats treated with alendronate, raloxifene, or strontium ranelate.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Humans; Raloxifene Hydrochloride; Rats; Rats, Wistar; Thiophenes; Tooth Extraction | 2021 |
Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Female; Femur; Fracture Healing; Mice; Osteogenesis; Osteogenesis Imperfecta; Thiophenes | 2021 |
Bone matrix quality in paired iliac bone biopsies from postmenopausal women treated for 12 months with strontium ranelate or alendronate.
Topics: Alendronate; Biopsy; Bone Density; Bone Density Conservation Agents; Bone Matrix; Female; Humans; Ilium; Osteoporosis, Postmenopausal; Postmenopause; Thiophenes | 2021 |
Strontium ranelate improves post-extraction socket healing in rats submitted to the administration of bisphosphonates.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Rats; Thiophenes; Tooth Extraction | 2022 |